315. Deputy Ken O'Flynn asked the Minister for Health whether the Health Service Executive has completed, or is in the process of completing, any National Centre for Pharmacoeconomics Rapid Review, Health Technology Assessment, or other formal evaluation for tirzepatide (mounjaro) and semaglutide (wegovy) for obesity or weight management; the date on which each assessment commenced; the current stage reached in each case; and the expected month in 2026 in which a pricing and reimbursement decision will be brought to the HSE senior leadership team. [10654/26]

Summary

315. Deputy Ken O'Flynn asked the Minister for Health whether the Health Service Executive has completed, or is in the process of completing, any National Centre for Pharmacoeconomics Rapid Review, Health Technology Assessment, or other formal evaluation for tirzepatide (mounjaro) and semaglutide (wegovy) for obesity or weight management; the date on which each assessment commenced; the current stage reached in each case; and the expected month in 2026 in which a pricing and reimbursement decision will be brought to the HSE senior leadership team. [10654/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 11 February 2026

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.